[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627260":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":76,"collaborators":11,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":11,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Oncolytics Biotech","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL",null,[13,14,15],"Drug: Bevacizumab","Drug: FOLFIRI","Drug: Pelareorep",{"label":17,"type":10,"description":11,"interventionNames":18},"Arm B",[13,14],[20,27,31],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Bevacizumab","Bevacizumab (5 mg\u002Fkg) IV infusion",[9,17],[26],"Avastin",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"FOLFIRI","irinotecan (180mg\u002Fm2), leucovorin 400 mg\u002Fm2 ± 5-FU (400 mg\u002Fm2) IV infusion",[9,17],{"type":21,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Pelareorep","pelareorep 4.5 x 10\\^10 TCID50 IV infusion",[9],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Name: Reference Study ID Number: REO 033","CONTACT","+1 (858) 247- 7829","REO-033@oncolytics.ca",[42,56,66],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":11},"Central Alabama Research","RECRUITING","Homewood","Alabama","35209","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-86.80082,33.47177,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":59,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":11},"Summit Health Cancer Center","Florham Park","New Jersey","07932",{"type":51,"coordinates":62},[63,64],-74.38821,40.78788,{"lat":64,"lon":63},{"facility":67,"status":44,"city":68,"state":69,"zip":70,"country":48,"countryCode":49,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"Gabrail Cancer Center","Canton","Ohio","44718",{"type":51,"coordinates":72},[73,74],-81.37845,40.79895,{"lat":74,"lon":73},{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100627260","phase-2-folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer-100627260",false,"NCT07446322","FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer","Inclusion Criteria:\n\n* Histologically confirmed cancer of the colon or rectum with documented metastasis\n* Measurable disease per RECIST v. 1.1\n* Not candidates for curative surgery or curative radiation\n* Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin\n* Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab\n* Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H\u002Fnon dMMR) tumor status per a standard local testing method\n* Tumor confirmed to harbor a known RAS mutation per a standard local testing method\n* ECOG performance status of 0 or 1\n* Patients must have adequate hematological, renal, and hepatic function\n* Female patients of childbearing potential must have a negative pregnancy test\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Undergone systemic chemotherapy, radiotherapy, or surgery, \\\u003C4 weeks before study treatment\n* Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment\n* Prior treatment with irinotecan\n* Symptomatic brain metastases\n* Active autoimmune disease\n* Receiving immunosuppressive or myelosuppressive medications\n* Active, uncontrolled infections\n* Known HIV infection or active hepatitis B or C that requires anti-viral treatment\n* History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ\n* History of allergy or known hypersensitivity to any of the study drugs, study drug classes,\n* Uncontrolled or severe cardiac disease\n* Received any vaccine within 28 days prior to first study treatment","ALL","18 Years",{"count":88,"type":89},60,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.",[95,96,97],"Ras-mutated Metastatic Colorectal Cancer","mCRC","MSS Metastatic Colorectal Cancer","2026-06-04",{"date":100,"type":101},"2026-06-08","ACTUAL",{"date":103,"type":101},"2026-04-30",{"date":105,"type":89},"2030-04-30",{"name":5,"class":6},3]